The medical community is abuzz with anticipation surrounding retatrutide, a innovative dual GIP and GLP-1 target that’s demonstrating significant potential in clinical trials for treating obesity. Unlike some current weight loss treatments, retatrutide appears to deliver a significant substantial decrease in body mass and enhance metabolic marker